Tissue RepairASX:TRP EV-to-FCF is 0.39 as of Jun. 30, 2026, which is 43% below its 10-year median of 0.68. Among 331 Biotechnology companies, Tissue Repair ranks better than 88.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tissue Repair's Enterprise Value is A$-2.25 Mil.
Tissue Repair's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.70 Mil. Therefore, Tissue Repair's EV-to-FCF for today is 0.39.
The historical rank and industry rank for Tissue Repair's EV-to-FCF or its related term are showing as below:
ASX:TRP'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.03 Med: 0.68 Max: 2.62
Current: 0.34
During the past 5 years, the highest EV-to-FCF of Tissue Repair was 2.62. The lowest was -3.03. And the median was 0.68.
ASX:TRP's EV-to-FCF is ranked better than 88.52% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs ASX:TRP: 0.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tissue Repair's PE Ratio (TTM) for today is calculated as:
Tissue Repair's share price for today is A$0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Repair's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tissue Repair EV-to-FCF Related Terms
Tissue Repair EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Tissue Repair's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tissue Repair's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Repair EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Repair's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tissue Repair's EV-to-FCF falls into.
Tissue Repair's current Enterprise Value is A$-2.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Repair's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Repair (ASX:TRP) has a EV-to-FCF of 0.39 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tissue Repair and its competitors. This is 43% below median its historical median of 0.68. According to the industry distribution chart, Tissue Repair ranks #38 out of 331 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Tissue Repair's EV-to-FCF too high?
Tissue Repair's current EV-to-FCF of 0.39 is 43% below median its 10-year median of 0.68. The Biotechnology industry median EV-to-FCF is 15.57. Tissue Repair's value of 0.39 is 97.5% below this industry median. Based on the distribution chart, Tissue Repair ranks #38 out of 331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Tissue Repair's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tissue Repair ranks #38 out of 331 companies for EV-to-FCF. This places Tissue Repair in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.57. Tissue Repair's value of 0.39 is 97.5% below this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 15.57, Tissue Repair has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Repair's current EV-to-FCF of 0.39 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tissue Repair and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Repair's current EV-to-FCF is 0.39, which is 43% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Repair stock overvalued right now?
Tissue Repair (ASX:TRP) has a current EV-to-FCF of 0.39. The current EV-to-FCF is 0.39, which is 43% below median its 10-year median of 0.68 and 97.5% below the Biotechnology industry median of 15.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tissue Repair (ASX:TRP), the current EV-to-FCF is 0.39 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRP has been successfully added to your 